RRM1
Ribonucleoside-diphosphate reductase large subunit
As of the edition of 20 October 2026, RRM1 (ribonucleoside-diphosphate reductase large subunit, UniProt P23921) has 9 drugs tested at it and 17 companies on the list, 2 on route A and 2 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P23921
- How well studied
- Drug target: an approved drug acts on it
- Where it sits in the cell
- Inside the cell
- Solved structures
- 12
- Disease areas
- Cancer; Digestive system; Hormones; Blood and lymph; Immune system; Lungs and airways; Urinary and reproductive; Pregnancy and women's health
- Registered trials of its drugs
- 3,026
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 4 |
| Active | 2 |
| Went quiet | 1 |
| Stopped | 2 |
| Total | 9 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Gemcitabine | Marketed | Phase 4 | none listed |
| Fludarabine phosphate | Marketed | Phase 4 | none listed |
| Clofarabine | Marketed | Phase 3 | none listed |
| Motexafin gadolinium | Stopped | Phase 3 | none listed |
| Triapine | Stopped | Phase 3 | none listed |
| TAR-200 | Active | Phase 3 | none listed |
| Gallium citrate | Marketed | Phase 3 | none listed |
| Tezacitabine anhydrous | Went quiet | Phase 2 | none listed |
| FF-10832 | Active | Phase 2 | none listed |
9 of 9 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 2 |
| Route B | 2 |
| Engaged | 8 |
| Undetermined | 5 |
| Total on the list | 17 |
The other 14 companies at RRM1
In the product17 companies in all; 14 are not named here, and no score is.
See the 17 companies at RRM1, ranked, with the facts behind eachRequest access. Nothing is shown until you do.